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Abstract
Background—The performance of automated algorithms for childhood diabetes case 
ascertainment and type classification may differ by demographic characteristics.
Objective—This study evaluated the potential of administrative and electronic health record 
(EHR) data from a large academic care delivery system to conduct diabetes case ascertainment in 
youth according to type, age and race/ethnicity.
Subjects—57,767 children aged <20 years as of December 31, 2011 seen at University of North 
Carolina Health Care System in 2011 were included.
Methods—Using an initial algorithm including billing data, patient problem lists, laboratory test 
results and diabetes related medications between July 1, 2008 and December 31, 2011, 
presumptive cases were identified and validated by chart review. More refined algorithms were 
evaluated by type (type 1 versus type 2), age (<10 versus ≥10 years) and race/ethnicity (non-
Hispanic white versus “other”). Sensitivity, specificity and positive predictive value were 
calculated and compared.
Results—The best algorithm for ascertainment of diabetes cases overall was billing data. The 
best type 1 algorithm was the ratio of the number of type 1 billing codes to the sum of type 1 and 
type 2 billing codes ≥0.5. A useful algorithm to ascertain type 2 youth with “other” race/ethnicity 
was identified. Considerable age and racial/ethnic differences were present in type-non-specific 
and type 2 algorithms.
Conclusions—Administrative and EHR data may be used to identify cases of childhood 
diabetes (any type), and to identify type 1 cases. The performance of type 2 case ascertainment 
algorithms differed substantially by race/ethnicity.
Keywords
childhood diabetes; case ascertainment; type classification; electronic health record; administrative 
data
Ongoing surveillance of childhood diabetes in the U.S. is needed to understand the trends in 
incidence and prevalence, and to anticipate health care delivery needs. The SEARCH for 
Diabetes in Youth Study (SEARCH) (1) documented an increase in the prevalence of type 1 
and type 2 diabetes from 2001 to 2009 (2, 3). From 2010 to 2050, the number of youth with 
type 1 and type 2 diabetes is projected to increase by another 23% and 49%, respectively, 
even assuming no change in incidence since 2002 (4).
Surveillance of childhood diabetes is challenging. First, we are unable to employ existing 
national surveillance systems such as the National Health and Nutrition Examination Survey 
(NHANES) because childhood diabetes is uncommon; NHANES (1999-2002) yielded 
only18 self-reported cases of diabetes among youth aged 12 to 19 years (5). Second, 
ascertainment of childhood diabetes cases is often costly in terms of time and financial 
resources. Currently the SEARCH study conducts validation of potential cases by manual 
review of medical records which is expensive, although the resulting case ascertainment is 
estimated to be very complete (i.e., >90% for both prevalent and incident cases) based on 
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capture-recapture analyses (6). Third, a useful childhood diabetes surveillance system 
should be able to discriminate between types of diabetes in different age, and racial/ethnic 
groups as the distribution of childhood diabetes varies by type, age and race/ethnicity (7, 8); 
and both etiology and treatment differ by diabetes type (7, 9-11).
The increasing utilization of computerized medical information systems may provide timely 
data for diabetes surveillance with substantially reduced cost relative to traditional 
approaches (12-14). Approaches to identify diabetes cases and classify type have been 
explored using administrative data (15-22), and electronic health record (EHR) data (23-26). 
Among all childhood diabetes algorithms in the literature, only two explored type-specific 
algorithms (21, 23). None of these studies evaluated algorithm performance according to age 
and race/ethnicity. In the U.S., it is not known whether administrative and EHR data from a 
large academic care delivery system can be used to accurately differentiate between 
childhood type 1 and type 2 diabetes (i.e., through use of type-sensitive algorithms) or 
whether such data can only identify cases without regard to type (i.e., through use of type-
insensitive algorithms). It is also not known whether the performance of automated 
algorithms differs by age and race/ethnicity.
Our objective was to identify algorithms with high performance, as demonstrated by high 
sensitivity, specificity, and positive predictive value (PPV), with a goal to efficiently 
identify diabetes cases and classify type in youth, overall and by age and race/ethnicity in a 
large academic care delivery system caring for patients with all payment sources, utilizing 
administrative and EHR data from the University of North Carolina Health Care System 
(UNCHCS).
Methods
The UNCHCS is a large not-for-profit integrated academic health care system located in 
central North Carolina, caring for a broad range of patients including those insured by 
Medicaid or without insurance. With a central 800-bed tertiary care center, and through its 
network of primary care and specialty physician practices located in 5 counties, UNC cares 
for over 800,000 people annually. Among insured patients, the predominant system of care 
in North Carolina is fee for service, with elements of care management.
Data sources
Three independent sources of data, presented below, were utilized from the Carolina Data 
Warehouse for Health (CDW-H), an enterprise-wide data warehouse within UNCHCS.
EHR data included demographics; outpatient medication lists; clinic, procedure, and 
hospitalization notes; patient problem lists; and laboratory test results. The outpatient 
medication list is a regularly updated record of active medications patients report being 
prescribed or taking, as well as inactive medications patients previously reported or were 
prescribed. The patient problem list includes ICD-9-CM codes for patients’ past and current 
illnesses. Laboratory data are sourced from laboratories both internal and external to 
UNCHCS, from which we identified dates and results for tests of fasting or random blood 
glucose as well as HbA1c, diabetes auto-antibodies (GAD65, IAA and ICA), and C-peptide.
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Inpatient medication order data were obtained from the Computerized Provider Order Entry.
Billing data included physician reimbursements and hospital (facility) charges accrued 
during outpatient and inpatient visits. Billing data, consisting of ICD-9-CM codes for each 
patient-visit, were captured separately for outpatient and inpatient visits. Diagnosis codes 
recorded at discharge, not at admission, were used for this analysis. The following diabetes-
related ICD-9-CM codes were used: 250.xx (diabetes mellitus); 775.1 (neonatal diabetes); 
648.0x (diabetes in pregnancy, non-gestational); 357.2 (diabetic neuropathy); 362.0x 
(diabetic retinopathy); and 366.41 (diabetic cataract).
This study was approved by the Institutional Review Board at the University of North 
Carolina at Chapel Hill.
Study population
Study population—The population of interest was defined as all children < 20 years of 
age as of December 31, 2011 who were seen by a health care provider at UNCHCS at least 
once for any reason in 2011.
Case ascertainment—An initial algorithm was applied to the study population to 
identify presumptive diabetes cases who met any criteria in the initial algorithm at any time 
from July 1, 2008 to December 31, 2011. The initial algorithm was designed to ensure very 
high sensitivity; thus, children not identified by this initial algorithm were assumed to not 
have diabetes (i.e., true negatives). The initial algorithm included the following: 1) ≥1 
HbA1c ≥ 6.0% (42 mmol/mol); or 2) ≥2 random blood glucose ≥ 200mg/dL on different 
days or ≥1 fasting blood glucose ≥126mg/dL; or 3) ≥1 patient problem list diabetes-related 
ICD-9-CM codes; or 4) ≥1 billing data diabetes-related ICD-9-CM codes; or 5) ≥1 diabetes-
related medications, including insulin, glucagon, metformin, sulfonylurea, GLP-1 receptor 
agonists, thiazolidinediones and other hypoglycemic agents. The time period allowed to find 
evidence for diabetes reflected the SEARCH study protocol for prevalent case 
ascertainment.
Diabetes case validation
Using the SEARCH case validation approach (1), diabetes status of the presumptive cases 
and diabetes type of true cases were determined by presence of a diagnosis of diabetes in the 
EHR in one or more notes written by health care providers (gold standard). Five reviewers 
were trained using the SEARCH standardized protocol by a member of the SEARCH team 
(J.T.) who has 10 years of experience with the SEARCH case ascertainment protocol. Each 
week, 5% of the records reviewed by each reviewer were validated by the trainer. If any 
discrepancies were found, these were discussed immediately.
A case validation form was used to collect presumptive cases’ demographics, prevalent 
diabetes status, initial and most recent diabetes type and associated diagnosis date, and 
presence of diabetic ketoacidosis (DKA) and diabetes auto-antibodies tests within 6 months 
of diagnosis. The most recent diabetes type recorded by the provider was used.
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Criteria for evaluating algorithms’ performance
True diabetes cases and their type validated by the standardized medical record review 
described above established our “gold standard”. Diabetes type-insensitive algorithms were 
evaluated within the full study population while the type-sensitive algorithms were 
evaluated among true diabetes cases.
No established cutpoints were available to evaluate the usefulness of algorithms 
quantitatively. Some attributes considered crucial for public health surveillance systems 
include simplicity, timeliness, sensitivity and PPV (27). High sensitivity is crucial for 
identifying most of the cases. High PPV is preferred to reduce the number of false positives 
while high specificity is important to distinguish between type 1 and type 2 youth. Thus, 
sensitivity, specificity and PPV are our primary outcomes of interest, and a promising 
algorithm should yield values approaching or greater than 90%.
Evaluation of type-insensitive and type-sensitive case ascertainment algorithms
The sensitivity, specificity, and PPV were computed for each of the five criteria listed in the 
initial algorithm above, and combinations thereof, relative to ascertainment of diabetes 
regardless of type. The capacity to ascertain type 1 and type 2 cases was explored using 
various combinations of ICD-9-CM 250.xx billing codes, outpatient medications, and 
laboratory test results. Multiple instances of the same laboratory tests and billing codes on 
the same day were counted only once; only the highest laboratory value in a day was 
retained for analyses. Ratios of the number of type 1 or type 2 billing codes to all ICD-9-CM 
250.xx billing codes identified within the whole 3.5 years surveillance window were also 
considered (24). Specifically, the ratio for type 1 algorithm was calculated as the number of 
type 1 billing codes divided by the total number of type 1 and type 2 billing codes; the ratio 
for type 2 algorithm was calculated as the number of type 2 billing codes divided by the total 
number of type 1 and type 2 billing codes.
Inpatient medication data included in the initial algorithm to ensure high sensitivity were 
excluded for evaluation of the algorithms, because among 59 presumptive cases whose only 
indication of diabetes was inpatient use of diabetes-related medications, none were true 
cases. Despite excluding inpatient medication data, these 59 presumptive cases were 
included in the analyses.
Given the importance of age and race/ethnicity in characterizing the prevalence of childhood 
diabetes, we evaluated the performance of the algorithms within two age groups (< 10 vs ≥ 
10 years) since type 2 diabetes is rare under the age of 10 (8), and two racial/ethnic groups, 
non-Hispanic white (NHW) versus “other” (7, 8). The other reason to select age 10 as the 
cutpoint is due to its common use in the literature as a criterion to differentiate between type 
1 and type 2 diabetes in children (21, 23). Nevertheless, we should be aware of potential bias 
that may result from this choice.
Data analyses were performed using SAS version 9.3 (SAS Institute, Cary, NC).
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Results
Demographic and clinical characteristics of the study population
The initial algorithm identified 1,348 presumptive diabetes cases from the population of 
57,767 children with any health care encounters in 2011 (Table 1). Review of the medical 
records for these 1,348 presumptive cases yielded 537 true cases: 405 type 1, 86 type 2 and 
46 cases of other type. The mean age and standard deviation (SD) of true diabetes cases, 
14.4 (4.1) years, was greater than that of the overall study population, 8.6 (6.2) years, and 
presumptive cases, 11.1 (6.5) years. Mean diagnosis age (SD) was 7.9 (4.3) years for type 1 
and 12.9 (2.3) years for type 2. The prevalence of DKA within 6 months of diagnosis was 
25% among diabetes cases. Nearly half of type 2 youth used insulin and 9% of type 1 youth 
used metformin.
Performance of diabetes type-insensitive algorithms
Full sample—The specificity of all type-insensitive algorithms was >99% (Table 2 and 
Table 3). Of the 5 individual criteria evaluated, the glucose criterion captured the most 
presumptive cases, but also the most false positives indicated by the lowest PPV (95% 
confidence interval (CI)) of 45.9% (42.5%, 49.2%) (Table 2). Interestingly, of the 435 
children who met only the glucose criterion, only 1 was diagnosed with diabetes 
(Supplemental Table 1, specific data combinations). Billing data was the best single 
criterion. The sensitivity (95% CI) was 97.0% (95.6%, 98.5%) while the PPV (95% CI) was 
82.2% (79.2%, 85.2%). The patient problem list had the highest PPV of 97.0% (94.9%, 
99.0%), but the sensitivity was only 48.0% (43.8%, 52.3%). Combining the patient problem 
list and billing data together (sensitivity=97.2% (95.8%, 98.6%); PPV=81.8% (78.8%, 
84.8%)) did not result in improved performance compared to use of billing data alone as 262 
out of 266 diabetes cases captured by the patient problem list were flagged by billing data as 
well (data not shown). The sensitivity and PPV of the algorithm requiring ≥ 2 criteria met 
were 90.7% (88.2%, 93.1%) and 89.0% (86.4%, 91.7%), respectively. The performance of 
each specific combination of the data was listed in the Supplemental Table 1. The PPV was 
only 6.7% (4.9%, 8.5%) for children who met only one criterion.
Age and racial/ethnic subgroups—Although billing data was the best single criterion 
in the full sample, its PPV was 62.5% (54.1%, 70.9%) in children < 10 years of age 
compared to 87.2% (84.2%, 90.1%) in children ≥10 years of age (Table 2). The PPV of 
outpatient medications was higher in the younger group 84.1% (76.4%, 91.7%) compared to 
the older group 74.5% (70.9%, 78.2%). The algorithm that required meeting ≥2 criteria 
performed similarly in the two age groups. The greatest difference between age groups was 
seen using the algorithm that included fasting or random glucose values (PPV: 16.6% 
(13.1%, 20.1%) versus 75.1% (71.0%, 79.2%)). Regarding the racial/ethnic subgroups, the 
algorithms’ performances were generally better in the NHW group than in the “other” group 
(Table 3). The greatest difference between racial/ethnic groups was seen using HbA1c, 
which had a PPV of 91.4% (88.0%, 94.8%) in the NHW group compared to 65.3% (59.0%, 
71.6%) in the “other” group.
Zhong et al. Page 6
Pediatr Diabetes. Author manuscript; available in PMC 2015 December 01.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
Performance of diabetes type-sensitive algorithms
Type 1 algorithms—The algorithm requiring the ratio of the number of type 1 billing 
codes to the sum of type 1 and type 2 billing codes ≥0.5 had sensitivity, specificity and PPV 
>90% in both the full sample, and in all age and racial/ethnic subgroups (Table 4 and Table 
5), with the exception of specificity of 83.3% in children <10 years of age (95% CI was not 
computed due to only 6 true non-cases, so it’s not reliable). The algorithms’ performance 
was not improved with addition of laboratory data and outpatient medications data.
Type 2 algorithms—The algorithm requiring the ratio of the number of type 2 billing 
codes to the sum of type 1 and type 2 billing codes ≥0.4 had a sensitivity of 91.9% (86.1%, 
97.6%) and a PPV of only 57.2% (49.0%, 65.5%) in the full sample, but it had a sensitivity 
of 93.1% (86.6%, 99.6%), a specificity of 87.2% (81.8%, 92.6%) and a PPV of 74.0% 
(63.9%, 84.0%) in youth with “other” race/ethnicity (Table 5). With the addition of 
medication data, the PPV increased to 78.2% (69.0%, 87.4%), but the sensitivity decreased 
to 70.9% (61.3%, 80.5%) in the full sample. Generally, the type 2 algorithms had better 
performance in the “other” race/ethnicity group. Age subgroups were not evaluated because 
only 2 children < 10 years of age had type 2 diabetes.
Discussion
This study supports the use of automated algorithms from administrative and EHR data, 
with billing data as the best single data source, to ascertain cases of childhood diabetes 
overall, cases of type 1 diabetes, and cases of type 2 diabetes in youth who were not NHW. 
We found considerable age and racial/ethnic differences in performance of the five 
individual diabetes criteria and considerable racial/ethnic differences in performance of type 
2 algorithms. Minimal age and racial/ethnic differences were observed for type 1 algorithms. 
However, no internal and external validation of algorithms were performed for those 
algorithms.
Our results suggest that using billing data alone may facilitate identifying diabetes cases 
regardless of type. In fact, billing data was the best single criterion, with little gained from 
the use of additional data. Based on our 90% evaluation criteria, the algorithm that required 
meeting ≥2 criteria could also be used. Our study is consistent with most of the literature in 
regards to billing data being the best single criterion in identifying diabetes cases (17, 22).
Additionally, our study revealed that youth with diabetes whose race/ethnicity was other 
than NHW or those <10 years of age were more difficult to identify. Billing data may not be 
sufficient in those subpopulations. For younger youth, depending on the surveillance goals, 
outpatient medications or the algorithm requiring ≥2 criteria met may be more viable 
options. The caveat with the latter algorithm was that the individual criteria used between 
systems should be the same in order to have comparable accuracy. Similarly, Zgibor et al 
(28) pointed out the best algorithm was the one with two or more criteria met or an 
outpatient diagnosis code. However, this study was conducted in an adult population and 
with different individual criteria. When accounting for racial/ethnic differences, although 
billing data may still be the best, the accuracy of ascertainment (i.e., PPV) was less 
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preferable for the “other” race/ethnicity group. Similar decreases in PPV were observed for 
the algorithm requiring ≥2 criteria met in the “other” race/ethnicity group.
A useful diabetes surveillance system should be able to ascertain cases efficiently according 
to diabetes type. Our findings suggest that the best type 1 algorithm was the ratio of the 
number of type 1 billing codes to the sum of type 1 and type 2 billing codes ≥0.5. There 
were minimal differences in performance of type 1 algorithms across age and racial/ethnic 
groups. These results are consistent with previous studies that have reported that type 1 
youth are easier to accurately identify relative to type 2 youth (21, 23). Interestingly, the 
performance of type 1 algorithms was not improved with addition of medication and 
laboratory data. Our best type 1 algorithm satisfies the crucial attributes for public health 
surveillance systems including simplicity, sensitivity, PPV (27), and high specificity.
Type 2 algorithms were far from optimal in ascertaining type 2 cases overall. Age 
differences were not considered due to the fact that type 2 diabetes is exceedingly rare in 
youth with age <10 years (8); only two type 2 cases were identified in our population. The 
algorithms performed considerably better in the “other” race/ethnicity group compared to 
the NHW group. This may be related to the higher prevalence of type 2 diabetes in 
population subgroups other than NHW (8). The algorithm with the ratio of the number of 
type 2 billing codes to the sum of type 1 and type 2 billing codes ≥ 0.4 was the best with a 
sensitivity 93.1% (86.6%, 99.6%), a specificity of 87.2% (81.8%, 92.6%) and a PPV of 
74.0% (63.9%, 84.0%) among youth with “other” race/ethnicity. This performance seems 
acceptable if manual review of medical records is not an option in a system, given the 
evidence that childhood type 2 cases are more difficult to ascertain (21, 23). There were no 
useful type 2 algorithms for NHW youth. Thus, relying solely on automated algorithms for 
ascertaining type 2 youth from an overall sample of youth with diabetes or for NHW youth 
with diabetes may not be possible with current EHR and billing data. The low performance 
may be attributable to the fact that type 2 ICD-9-CM codes include unspecified diabetes 
type (29); insulin is commonly used in type 2 diabetes (9) and metformin is also used to treat 
polycystic ovarian syndrome and for weight control, leading to false positives (24). 
Together, these factors represent a significant barrier to developing a useful type 2 
algorithm.
Although we have highlighted some useful algorithms, the purpose was not to advocate 
using them in health systems directly without any validation study at present. Careful 
consideration should be given (e.g., the goal of the study) in terms of selecting an algorithm 
or developing a new one. Particularly, a small pilot validation study may be conducted 
within a system before implementing the algorithm in the whole system.
Differences in case ascertainment performance of HbA1c and fasting/random glucose 
criteria were observed according to race/ethnicity and age. Racial/ethnic differences were 
greatest for the HbA1c criterion. The PPV was considerably lower in the “other” race/
ethnicity group. When a cutpoint of 6.5% was used, a diagnostic value for diabetes in adults, 
instead of 6.0%, the sensitivity was similar, but the PPV was significantly improved for the 
“other” race/ethnicity group (93.2% versus 65.3%). The explanation may be that NHW 
youth had significantly lower HbA1c level compared to youth with “other” racial/ethnicity 
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in the general U.S. population (30), and diabetes population (31). There is currently no 
consistency about which HbA1c value should be used for surveillance; studies previously 
used 6.7% (32), 6.5% (19, 25), or a presence of HbA1c test regardless of value (26, 28). Our 
study used 6.0% to ensure very high sensitivity of the initial algorithm. The appropriate 
cutpoint of HbA1c value for surveillance should be further evaluated in other populations.
As for fasting/random glucose, the performance differed significantly by age groups. The 
PPV of the fasting/random glucose criterion (45.9%) was lower than that in the recent 
analysis by Lawrence et al. (>60%) (23); however, only six to twelve months of laboratory 
data were used in their study. In our study, the PPV increased to a comparable level of 
63.2% when one year of data was used while the sensitivity remained similar (data not 
shown). Our original low PPV may be driven by the younger age group rather than by the 
length of surveillance window, because the PPV was 75.1% in the older group in our study. 
In fact, the PPV increased only from 16.6% to 31.0% for age <10 years group using one 
year of data. Our population had a proportion of youth < 5 years of age twice that of the 
sample used in the study by Lawrence et al. (23) The findings of the present study suggest 
that glucose criterion may not accurately ascertain childhood diabetes cases in youth < 10 
years of age. The reasons may involve the fact that younger youth visit health system more 
frequently and a qualified glucose test result can frequently be triggered by conditions other 
than diabetes. Also, children with fasting glucose results pulled from EHR may not be truly 
fasting at the blood draw. Further, a fasting glucose result may be mislabeled as the random 
glucose result.
This study has several strengths. First, to the best of our knowledge, this is the first U.S. 
study to evaluate demographic differences in the performance of diabetes case ascertainment 
algorithms by diabetes type. Also, case ascertainment and type classification approaches for 
childhood diabetes have not been well explored, especially outside of Canada where health 
care is universal and the Kaiser Permanente, a large integrated health system (23). Our study 
identified useful algorithms that could greatly facilitate surveillance efforts. Furthermore, all 
presumptive cases were validated individually by review of the complete medical records, 
which served as our gold standard.
Limitations should be noted. First, our study population included all children < 20 years old 
who were seen at least once at UNCHCS in 2011. Therefore, the study population may not 
represent all youth served by UNCHCS. However, the DKA prevalence (25.0%) was the 
same as found in SEARCH (25.5%) (33), and use of diabetes medications was also similar 
(9). Hence, sampling bias likely posed little, if any, influence, with the assumption that 
youth with diabetes are regularly seen in a health care setting. Second, we made an 
assumption that children not selected by the initial algorithm were true negatives. It is 
possible that some true cases were not identified by our initial algorithm. However, in our 
data, children identified only by inpatient medications were all true negatives and only 1 of 
the 435 children captured only by glucose criterion had diabetes. In fact, the overall false 
positive proportion was 93.3% among youth who met only 1 criterion. With the very high 
proportion of false positives among children with only one criterion met and the very low 
prevalence of diabetes in children, it is exceedingly unlikely that false negative case 
numbers would be sufficiently high to impact our findings. Finally, this work applies to 
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estimation of prevalence of childhood diabetes, not incidence which would require 
ascertainment of diagnosis date.
In conclusion, automated algorithms from administrative and EHR data may be useful to 
ascertain cases of diabetes without regard to type, as well as cases of type 1 diabetes and 
cases of type 2 diabetes among youth with race/ethnicity other than NHW. Detailed review 
of medical records may be needed to ascertain type 2 cases in NHW youth accurately. 
Future work will be required to replicate our case ascertainment methodologies in other 
health systems to determine the generalizability and to inform the development of low-cost 
sustainable public health surveillance systems of childhood diabetes in the future.
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